Target Price | $762.52 |
Price | $589.48 |
Potential | 29.35% |
Number of Estimates | 28 |
28 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $762.52. This is 29.35% higher than the current stock price. The highest price target is $1,063.65 80.44% , the lowest is $548.43 6.96% . | |
A rating was issued by 34 analysts: 25 Analysts recommend Regeneron Pharmaceuticals to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 29.35% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
29 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.7b . This is 3.92% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.9b 4.92% , the lowest is $12.2b 14.24% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $13.7b | 3.84% |
2026 | $14.6b | 6.65% |
2027 | $16.1b | 10.67% |
2028 | $17.0b | 5.40% |
2029 | $17.9b | 5.58% |
2030 | $18.7b | 4.38% |
2031 | $19.3b | 3.28% |
2032 | $18.8b | 2.77% |
14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.6b . This is 0.21% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 37.21% , the lowest is $3.1b 31.57% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 1.17% |
---|---|---|
2025 | $4.6b | 3.00% |
2026 | $5.3b | 15.92% |
2027 | $6.1b | 15.49% |
2028 | $6.4b | 4.95% |
2029 | $7.1b | 11.19% |
2030 | $7.7b | 7.71% |
2031 | $8.0b | 4.42% |
2032 | $7.1b | 11.00% |
2024 | 33.10% | 8.72% |
---|---|---|
2025 | 33.39% | 0.88% |
2026 | 36.29% | 8.69% |
2027 | 37.87% | 4.35% |
2028 | 37.71% | 0.42% |
2029 | 39.72% | 5.33% |
2030 | 40.98% | 3.17% |
2031 | 41.44% | 1.12% |
2032 | 37.93% | 8.47% |
30 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.8b . This is 13.86% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 6.12% , the lowest is $3.2b 28.93% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.4b | 11.61% |
---|---|---|
2025 | $3.8b | 12.96% |
2026 | $4.3b | 11.59% |
2027 | $5.3b | 22.75% |
2028 | $5.8b | 9.86% |
2029 | $6.4b | 10.14% |
2030 | $6.9b | 7.98% |
2031 | $7.4b | 7.19% |
2032 | $7.1b | 3.13% |
2024 | 31.07% | 3.08% |
---|---|---|
2025 | 28.12% | 9.50% |
2026 | 29.43% | 4.66% |
2027 | 32.64% | 10.91% |
2028 | 34.02% | 4.23% |
2029 | 35.49% | 4.32% |
2030 | 36.72% | 3.47% |
2031 | 38.11% | 3.79% |
2032 | 37.97% | 0.37% |
30 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $36.10 . This is 12.06% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.47 8.33% , the lowest is $29.78 27.45% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $36.10 | 5.84% |
2026 | $40.28 | 11.58% |
2027 | $49.45 | 22.77% |
2028 | $54.32 | 9.85% |
2029 | $59.83 | 10.14% |
2030 | $64.61 | 7.99% |
2031 | $69.25 | 7.18% |
2032 | $67.09 | 3.12% |
Current | 14.57 | 53.74% |
---|---|---|
2025 | 16.57 | 13.72% |
2026 | 14.85 | 10.38% |
2027 | 12.10 | 18.52% |
2028 | 11.01 | 9.01% |
2029 | 10.00 | 9.17% |
2030 | 9.26 | 7.40% |
2031 | 8.64 | 6.70% |
2032 | 8.92 | 3.24% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 4.29 and an P/S ratio of 4.64 .
This results in the following potential growth metrics and future valuations:
Current | 4.12 | 54.77% |
---|---|---|
2025 | 4.29 | 4.21% |
2026 | 4.03 | 6.24% |
2027 | 3.64 | 9.64% |
2028 | 3.45 | 5.12% |
2029 | 3.27 | 5.29% |
2030 | 3.13 | 4.19% |
2031 | 3.03 | 3.18% |
2032 | 3.12 | 2.85% |
Current | 4.46 | 53.72% |
---|---|---|
2025 | 4.64 | 4.08% |
2026 | 4.35 | 6.23% |
2027 | 3.93 | 9.64% |
2028 | 3.73 | 5.12% |
2029 | 3.53 | 5.28% |
2030 | 3.39 | 4.19% |
2031 | 3.28 | 3.18% |
2032 | 3.37 | 2.85% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 04 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 04 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 04 2025 |
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Jul 23 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Jul 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 11 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Aug 04 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 04 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 04 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 04 2025 |
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Jul 23 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Jul 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.